Cargando…

On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study

BACKGROUND AND AIMS: No consensus has been established regarding optimal long-term maintenance therapy in symptomatic gastroesophageal reflux disease (GERD). The aim of this study was to compare the efficacies of on-demand and continuous therapy with esomeprazole as maintenance treatments for GERD....

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Joon Hyun, Koo, Ji Yeon, Kim, Kyeong Ok, Lee, Si Hyung, Jang, Byung Ik, Kim, Tae Nyeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221682/
https://www.ncbi.nlm.nih.gov/pubmed/30412065
http://dx.doi.org/10.1097/MD.0000000000012732
_version_ 1783369067470520320
author Cho, Joon Hyun
Koo, Ji Yeon
Kim, Kyeong Ok
Lee, Si Hyung
Jang, Byung Ik
Kim, Tae Nyeun
author_facet Cho, Joon Hyun
Koo, Ji Yeon
Kim, Kyeong Ok
Lee, Si Hyung
Jang, Byung Ik
Kim, Tae Nyeun
author_sort Cho, Joon Hyun
collection PubMed
description BACKGROUND AND AIMS: No consensus has been established regarding optimal long-term maintenance therapy in symptomatic gastroesophageal reflux disease (GERD). The aim of this study was to compare the efficacies of on-demand and continuous therapy with esomeprazole as maintenance treatments for GERD. METHODS: Patients with upper gastrointestinal (GI) endoscopy-proven GERD who received initial proton pump inhibitor (PPI) therapy for 8 weeks were randomized to an on-demand group (esomeprazole 40 mg) or a continuous group (esomeprazole 20 mg). Intensities and frequencies of heartburn and acid regurgitation were assessed using a 6-point Likert scale (0 = no symptoms; 5 = very severe symptoms) and a 6-point frequency scale (0 = none; 5 = symptoms for > 5 days per week) at baseline (start of maintenance treatment) and after 12 weeks of treatment. Alleviation of symptoms was quantified using percentages of patients with a Likert scale or frequency scale of 0 or 1. RESULTS: Of the 88 patients enrolled, 8 patients were excluded due to follow-up loss in early period of this study, and finally, 39 in the on-demand group and 41 in the continuous group were analyzed. No significant intergroup difference was found between Likert scale or frequency scale of heartburn or regurgitation at baseline. Percentages of symptom alleviations in the on-demand and continuous groups for intensity of heartburn were 56.4%/48.8% at baseline (P = .523) and 82.1%/87.8% at 12 weeks (P = .471), for frequency of heartburn were 61.5%/46.3% at baseline (P = .173) and 76.9%/87.8% at 12 weeks (P = .200), for intensity of regurgitation was 53.8%/43.9% at baseline (P = .374) and 82.1%/87.8% at 12 weeks (P = .471), and for frequency of regurgitation was 61.5%/56.1% at the baseline (P = .621) and 82.1%/82.9% at 12 weeks (P = .918), respectively. Furthermore, no significant intergroup difference was found for convenience of medication or subjective satisfaction. CONCLUSIONS: Intensities and frequencies of heartburn and regurgitation responded well to maintenance treatment in patients in the on-demand and continuous groups. On-demand therapy with esomeprazole 40 mg appears to be sufficient for maintenance treatment in GERD patients.
format Online
Article
Text
id pubmed-6221682
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-62216822018-12-04 On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study Cho, Joon Hyun Koo, Ji Yeon Kim, Kyeong Ok Lee, Si Hyung Jang, Byung Ik Kim, Tae Nyeun Medicine (Baltimore) Research Article BACKGROUND AND AIMS: No consensus has been established regarding optimal long-term maintenance therapy in symptomatic gastroesophageal reflux disease (GERD). The aim of this study was to compare the efficacies of on-demand and continuous therapy with esomeprazole as maintenance treatments for GERD. METHODS: Patients with upper gastrointestinal (GI) endoscopy-proven GERD who received initial proton pump inhibitor (PPI) therapy for 8 weeks were randomized to an on-demand group (esomeprazole 40 mg) or a continuous group (esomeprazole 20 mg). Intensities and frequencies of heartburn and acid regurgitation were assessed using a 6-point Likert scale (0 = no symptoms; 5 = very severe symptoms) and a 6-point frequency scale (0 = none; 5 = symptoms for > 5 days per week) at baseline (start of maintenance treatment) and after 12 weeks of treatment. Alleviation of symptoms was quantified using percentages of patients with a Likert scale or frequency scale of 0 or 1. RESULTS: Of the 88 patients enrolled, 8 patients were excluded due to follow-up loss in early period of this study, and finally, 39 in the on-demand group and 41 in the continuous group were analyzed. No significant intergroup difference was found between Likert scale or frequency scale of heartburn or regurgitation at baseline. Percentages of symptom alleviations in the on-demand and continuous groups for intensity of heartburn were 56.4%/48.8% at baseline (P = .523) and 82.1%/87.8% at 12 weeks (P = .471), for frequency of heartburn were 61.5%/46.3% at baseline (P = .173) and 76.9%/87.8% at 12 weeks (P = .200), for intensity of regurgitation was 53.8%/43.9% at baseline (P = .374) and 82.1%/87.8% at 12 weeks (P = .471), and for frequency of regurgitation was 61.5%/56.1% at the baseline (P = .621) and 82.1%/82.9% at 12 weeks (P = .918), respectively. Furthermore, no significant intergroup difference was found for convenience of medication or subjective satisfaction. CONCLUSIONS: Intensities and frequencies of heartburn and regurgitation responded well to maintenance treatment in patients in the on-demand and continuous groups. On-demand therapy with esomeprazole 40 mg appears to be sufficient for maintenance treatment in GERD patients. Wolters Kluwer Health 2018-10-26 /pmc/articles/PMC6221682/ /pubmed/30412065 http://dx.doi.org/10.1097/MD.0000000000012732 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Cho, Joon Hyun
Koo, Ji Yeon
Kim, Kyeong Ok
Lee, Si Hyung
Jang, Byung Ik
Kim, Tae Nyeun
On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
title On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
title_full On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
title_fullStr On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
title_full_unstemmed On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
title_short On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study
title_sort on-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: a randomized comparative study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221682/
https://www.ncbi.nlm.nih.gov/pubmed/30412065
http://dx.doi.org/10.1097/MD.0000000000012732
work_keys_str_mv AT chojoonhyun ondemandversushalfdosecontinuoustherapywithesomeprazoleformaintenancetreatmentofgastroesophagealrefluxdiseasearandomizedcomparativestudy
AT koojiyeon ondemandversushalfdosecontinuoustherapywithesomeprazoleformaintenancetreatmentofgastroesophagealrefluxdiseasearandomizedcomparativestudy
AT kimkyeongok ondemandversushalfdosecontinuoustherapywithesomeprazoleformaintenancetreatmentofgastroesophagealrefluxdiseasearandomizedcomparativestudy
AT leesihyung ondemandversushalfdosecontinuoustherapywithesomeprazoleformaintenancetreatmentofgastroesophagealrefluxdiseasearandomizedcomparativestudy
AT jangbyungik ondemandversushalfdosecontinuoustherapywithesomeprazoleformaintenancetreatmentofgastroesophagealrefluxdiseasearandomizedcomparativestudy
AT kimtaenyeun ondemandversushalfdosecontinuoustherapywithesomeprazoleformaintenancetreatmentofgastroesophagealrefluxdiseasearandomizedcomparativestudy